| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $42,349,749 ) (Continued on the next page) |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249689 | CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | 002 | 3 | NIH | 3/31/2022 | $613,483 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA252373 | RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER | 001 | 2 | NIH | 7/7/2022 | $15,401 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA252373 | RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER | 000 | 2 | NIH | 1/4/2022 | $173,243 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL151579 | Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms | 002 | 2 | NIH | 6/8/2022 | $48,329 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL151579 | Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms | 001 | 2 | NIH | 2/17/2022 | -$1 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL151579 | Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms | 000 | 2 | NIH | 2/2/2022 | $434,933 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA244101 | Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach | 000 | 3 | NIH | 7/18/2022 | $323,155 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DK125367 | Improving weight loss outcomes of black women using a culturally relevant, stress management enhancement behavioral weight loss intervention | 000 | 3 | NIH | 4/28/2022 | $648,070 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA239219 | Imaging Acidosis and Immune Therapy in PDAC | 001 | 3 | NIH | 6/23/2022 | $54,677 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA239219 | Imaging Acidosis and Immune Therapy in PDAC | 000 | 3 | NIH | 1/13/2022 | $615,155 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250018 | Functional characterization of prostate cancer risk loci by high throughput sequencing | 000 | 3 | NIH | 7/5/2022 | $366,164 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA230610 | Regulation of dendritic cell function and tumor immunity by TIM-3 | 000 | 4 | NIH | 8/4/2022 | $393,450 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA244100 | Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy | 001 | 3 | NIH | 5/13/2022 | $39,678 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA244100 | Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy | 000 | 3 | NIH | 3/10/2022 | $275,960 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233601 | Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | 001 | 3 | NIH | 6/10/2022 | $39,778 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233601 | Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | 000 | 3 | NIH | 2/24/2022 | $447,475 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA242742 | Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors | 000 | 3 | NIH | 7/12/2022 | $375,050 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA090314 | Behavioral Oncology Education & Career Development | 000 | 19 | NIH | 8/4/2022 | $322,699 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | UH3CA202970 | Validation of EGFR Protein Complexes as Molecular Diagnostics | 000 | 5 | NIH | 6/30/2022 | $137,649 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233487 | Optimal Decision Making in Radiotherapy Using Panomics Analytics | 000 | 5 | NIH | 7/19/2022 | $457,212 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA240434 | Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma | 000 | 4 | NIH | 7/21/2022 | $537,558 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA236034 | A Stepped-care Psychosocial Intervention for Brain Tumor Family Caregivers | 000 | 4 | NIH | 8/4/2022 | $391,136 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K08CA231454 | Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer | 001 | 4 | NIH | 7/27/2022 | $238,752 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA234021 | Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia | 000 | 4 | NIH | 7/31/2022 | $496,638 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241559 | Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation | 000 | 4 | NIH | 6/27/2022 | $385,581 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA250320 | The importance of CD4+ tumor-infiltrating lymphocytes (TIL) in adoptive cell transfer | 001 | 3 | NIH | 6/7/2022 | $716 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA250320 | The importance of CD4+ tumor-infiltrating lymphocytes (TIL) in adoptive cell transfer | 000 | 3 | NIH | 2/25/2022 | $38,748 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250514 | Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells | 003 | 4 | NIH | 6/13/2022 | $30,141 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K08CA237627 | Tumor suppressor roles of TFEB in the development and maintenance of myeloid leukemia | 000 | 4 | NIH | 8/1/2022 | $238,752 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241169 | Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on ?? T cells, in the bone microenvironment. | 001 | 3 | NIH | 7/7/2022 | $48,914 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241169 | Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on ?? T cells, in the bone microenvironment. | 000 | 3 | NIH | 2/23/2022 | $440,201 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA231952 | Partnering with a State Food Bank to Provide Tobacco Treatment to Underserved Smokers | 001 | 4 | NIH | 5/31/2022 | $48,448 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA231952 | Partnering with a State Food Bank to Provide Tobacco Treatment to Underserved Smokers | 000 | 4 | NIH | 11/8/2021 | $545,047 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233512 | Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands | 000 | 4 | NIH | 6/10/2022 | $385,581 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 002 | 4 | NIH | 6/17/2022 | $54,351 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 001 | 4 | NIH | 6/16/2022 | $430,000 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 3 | NIH | 11/26/2021 | $31,706 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA239214 | Local and systemic control of multiple myeloma colonization and growth by MMP-13 | 000 | 4 | NIH | 5/10/2022 | $431,630 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01FD006095 | PhI/II Study of CD8-Reduced T Cells for Treatment of MDS or AML IND17305 (12/30/2016) | 000 | 4 | FDA | 8/4/2022 | $239,390 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250276 | CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer | 000 | 3 | NIH | 4/25/2022 | $428,692 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA222215 | Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy | 000 | 5 | NIH | 7/15/2022 | $489,551 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA219389 | Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome | 000 | 5 | NIH | 6/14/2022 | $677,991 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA227073 | Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers | 001 | 5 | NIH | 5/23/2022 | $57,148 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA227073 | Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers | 000 | 5 | NIH | 11/23/2021 | $642,903 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA214647 | Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue | 000 | 5 | NIH | 6/10/2022 | $590,368 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA230042 | Investigation of NRF2-Dependent Metabolic Liabilities | 000 | 5 | NIH | 7/25/2022 | $393,450 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA223823 | Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer | 001 | 5 | NIH | 5/31/2022 | $58,359 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA223823 | Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer | 000 | 5 | NIH | 11/9/2021 | $656,537 |
| | 2022 | 2022 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA235032 | Phase II Clinical trial of GTC in Men on Active Surveillance | 000 | 4 | NIH | 7/28/2022 | $10,124 |
|
